Danazol administration after gonadotrophin-releasing hormone analogue reduces rebound of uterine myomas.
We report the results of administration of danazol after suspension of gonadotrophin-releasing hormone analogue (GnRHa) therapy for uterine myomas. A total of 21 women with uterine myomas was treated with 100 mg danazol for 6 months after GnRHa therapy. Uterine volume and endocrine status were monitored monthly by ultrasound and assay of plasma gonadotrophins, oestradiol and progesterone. The results show a rebound of uterine volume about 30% less than in controls at the end of danazol therapy. Menstrual cyclicity returned after 65 +/- 3 days in 16 subjects and five patients remained amenorrhoeic. Hormone assays confirmed renewed ovarian function in the women whose menstrual periods returned. Bone mineral content was substantially reduced during GnRHa treatment but improved significantly during danazol therapy even in the women who remained amenorrhoeic. These results show the utility of danazol in prolonging the therapeutic effects of GnRHa. The mechanism by which danazol inhibits rebound of uterine volume may be due to its antiprogesterone effects on uterine myomas.
De Leo
V
V
Department of Obstetrics and Gynaecology, University of Siena, Italy.
Morgante
G
G
Lanzetta
D
D
D'Antona
D
D
Bertieri
R S
RS
D000328:Adult; D003613:Danazol / Q000008:administration & dosage*; D004351:Drug Resistance; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004965:Estrogen Antagonists; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol